News
November 11, 2025
March Biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma
March announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, the company’s CD5 CAR T cell therapy
November 3, 2025
March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting
March will will present interim clinical data from its ongoing Phase 2 trial of MB-105 during an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting
April 22, 2025
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
March Biosciences announced that the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for r/r T cell lymphoma
Publications
July 16, 2024
We demonstrate that the expression of a chimeric antigen receptor (CAR) targeting CD5, a prominent pan-T cell antigen, induces rapid internalization and complete loss of the CD5 protein on T cells, protecting them from self-targeting.
March 28, 2024
Phase 1 trial shows autologous CD5.CAR T cells are safe and effective in r/r T-cell lymphoma with a 44% overall response rate, promising advances in T-cell malignancy treatment.
June 2, 2023
We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.